Common warts
Conditions
Interventions
The following 4 groups will be administered, and KNP2002 is administered repeatedly for 12 weeks.
KNP2002 high dose
KNP2002 moderate dose group
KNP2002 low dose group
Placebo group
Sponsors
Sato Katsuhiko
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Subjects aged 15 to 49 at the time of obtaining consent 2. Subjects with typical common warts on the upper extremities or lower extremities excluding the soles of the feet. 3. Subjects who agree to contraception from obtaining consent to 4 weeks after the end of administration 4. Subjects who have given their voluntary written consent to participate in this clinical trial
Exclusion criteria
Exclusion criteria: 1. Subjects with 5 or more warts due to human papillomavirus (HPV) infection on the upper or lower limbs 2. Subjects who are scheduled to undergo treatment such as physical therapy or chemotherapy for warts 3. Subjects with a history of allergy to topical skin preparations 4. Subjects with a history of malignant tumor within 5 years before administration of study drug 5. Subjects with any of the following diseases Malignant tumor Serious heart disease Poorly controlled diabetes, hypertension 6. Women who are pregnant, may become pregnant, or are breastfeeding.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1. Safety evaluation items Adverse event 2. Efficacy endpoints Wart area change from the start of administration (at endpoint) | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Change in wart area over time 2. Wart disappearance rate 3. Wart improvement rate | — |
Contacts
Public ContactKatsuhiko Sato
KinoPharma Inc.
Outcome results
None listed